Can Adagio’s Adintrevimab Hold Up Against Omicron BA.2?
Executive Summary
The company will seek an EUA for the COVID-19 antibody after trial data indicated efficacy against Omicron, but studies have called into question its potency against the rapidly expanding subvariant.
You may also be interested in...
Coronavirus Update: FDA Tries To Control J&J’s Vaccine, Extended Use Of Paxlovid
The FDA has also moved to limit use of J&J’s COVID-19 vaccine amid reports of rare but dangerous blood clots, while Regeneron highlighted efforts to get approval for REGEN-COV in its Q1 earnings.
US Restricts Use of GSK/Vir’s Xevudy, Deemed ‘Unlikely’ To Help Against Rising Omicron Variant
The constantly mutating SARS-CoV-2 has evaded yet another antibody therapy, but Vir and GSK hope that a higher dose of Xevudy could retain some efficacy against BA.2.
Antibody Therapies Vs. Omicron: Vir Stands Up But Regeneron And Lilly Fail
New studies show Regeneron and Lilly’s leading COVID-19 antibody cocktails are ‘inactive’ against Omicron but there is better news for Vir, AstraZeneca and Adagio.